RxDoctor Payments Data

May Flores, MD

Family Medicine · Uniontown, PANPI 1134216757

Payments from drug & device makers

$23,214in general payments, 2019–2025

Across 1,571 payments — averaging $14.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$3K
  • AstraZeneca$2K
  • GSK$2K
  • Boehringer Ingelheim$2K
  • Pfizer$2K
  • plus $10K from 50 others

What the payments were for

  • Food & beverage$23,166100%
  • Education$480%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,214 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$112,086
Medicare patients
203
Services billed
1,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban282$267,064
FarxigaDapagliflozin Propanediol278$262,944
Trelegy ElliptaFluticasone/Umeclidin/Vilanter226$185,594
OzempicSemaglutide108$155,063
TrulicityDulaglutide127$140,688
JardianceEmpagliflozin126$120,187
MounjaroTirzepatide86$112,431
EntrestoSacubitril/Valsartan79$74,335
LinzessLinaclotide73$52,630
RybelsusSemaglutide38$52,392
XareltoRivaroxaban63$45,891
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr68$36,590
TradjentaLinagliptin41$25,199
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog34$24,564
Humalog Kwikpen U-200Insulin Lispro21$23,817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta, Symbicort$2,099$273,721304 claims
PfizerEliquis$1,543$267,064282 claims
Lilly USA, LLCTrulicity, Mounjaro$1,505$253,119213 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$2,000$242,345340 claims
Novo NordiskOzempic, Rybelsus$2,863$207,455146 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Stiolto Respimat$1,760$169,474209 claims
NovartisEntresto$596$74,33579 claims
AbbVieLinzess$3,074$52,63073 claims
Johnson & JohnsonXarelto$206$45,89163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Uniontown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →